ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
Samuel J. Daniels(University of Southern Denmark), Jacob George(University of Dundee), Indra Neil Guha(Nottingham University Hospitals NHS Trust), Ahmed M. Hashem(Minia University), Jun Akiba(Kurume University), Aleksander Krag(University of Southern Denmark), Diana Julie Leeming(Nordic Bioscience (Denmark)), M.A. Karsdal(Nordic Bioscience (Denmark)), Philip Kaye(Nottingham University Hospitals NHS Trust), Mohammed Eslam(The University of Sydney), Jane I. Grove(Nottingham University Hospitals NHS Trust), Mette Juul Nielsen(Nordic Bioscience (Denmark)), Guruprasad P. Aithal(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Leon A. Adams(The University of Western Australia), Takumi Kawaguchi(Kurume University), Duncan McLeod(Westmead Hospital), Bastiaan de Boer(Fiona Stanley Hospital), Takuji Torimura(Omuta hospital)
Cited by 264
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k